Cargando…

Response to Trepanowski et al.’s “Delays in melanoma presentation during the COVID-19 pandemic: a nationwide multi-institutional cohort study”

Detalles Bibliográficos
Autores principales:	Drumm, Claire, Griffin, Ciara, Van Baarsel, Susan, Quigley, Claire, Madden, Stephen, Naidoo, Jarushka, Eustace, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165503/ https://www.ncbi.nlm.nih.gov/pubmed/37088198 http://dx.doi.org/10.1016/j.jaad.2023.02.066

Ejemplares similares

Melanoma of unknown primary: a case series
por: Doyle, Claire, et al.
Publicado: (2022)

Delays in melanoma presentation during the COVID-19 pandemic: A nationwide multi-institutional cohort study
por: Trepanowski, Nicole, et al.
Publicado: (2022)

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
por: Rosner, Samuel, et al.
Publicado: (2020)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
por: Bredin, Philip, et al.
Publicado: (2022)

Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity
por: Cluxton, Christopher, et al.
Publicado: (2023)

Response to Park et al.
por: Barbier, Mathieu, et al.
Publicado: (2021)

Reply to Farmakiotis et al
por: Waddington, Claire S., et al.
Publicado: (2014)

Masters et al. Respond
por: Masters, Ryan K., et al.
Publicado: (2017)

Immune-Related Adverse Events: A Case-Based Approach
por: Connolly, Caoilfhionn, et al.
Publicado: (2019)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
por: Balaji, Aanika, et al.
Publicado: (2020)

Reply to Gueret et al. and to Hammond et al.
por: Brown, Ryan M., et al.
Publicado: (2020)

Successful Treatment of Scar Pain with Scrambler Therapy
por: Yarchoan, Mark, et al.
Publicado: (2019)

Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer
por: Wills, Beatriz, et al.
Publicado: (2018)

From expert recommendations to multidisciplinary team decisions: a way to set out the novel perioperative options for patients with non-small-cell lung cancer
por: Banna, Giuseppe Luigi, et al.
Publicado: (2022)

Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer
por: Al-Rajabi, Taiseer, et al.
Publicado: (2023)

Letter to the Editor: A Response to the Comments of Borderas et al. (2007)
por: Quigley, J.D., et al.
Publicado: (2007)

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
por: Page, David B, et al.
Publicado: (2014)

Point-of-care ultrasound: reply to Andronikou et al. and Györgyi et al.
por: Arthurs, Owen J., et al.
Publicado: (2021)

Cryobiopsy Compared with Surgical Lung Biopsy in ILD: Reply to Maldonado et al., Froidure et al., Bendstrup et al., Agarwal et al., Richeldi et al., Rajchgot et al., and Quadrelli et al.
por: Romagnoli, Micaela, et al.
Publicado: (2019)

Evaluation of an ultrasound program in nationwide Continuing Professional Development (CPD) in Korean public health and medical institutions
por: Kim, Claire Junga, et al.
Publicado: (2022)

The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?
por: Page, David B, et al.
Publicado: (2015)

Reply by Gattinoni et al. to Hedenstierna et al., to Maley et al., to Fowler et al., to Bhatia and Mohammed, to Bos, to Koumbourlis and Motoyama, and to Haouzi et al.
por: Gattinoni, Luciano, et al.
Publicado: (2020)

Yoon et al. Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry
por: Lee, Jeong-Hoon
Publicado: (2022)

Reply to Cottin et al., to Johannson et al., to Scholand and Wells, and to Crowley et al.
por: Raghu, Ganesh, et al.
Publicado: (2022)

Response to Sadek et al. and Kotlikoff et al.
por: Andersen, Ditte Caroline, et al.
Publicado: (2014)

Reply to Lescoat et al. and to Khamis et al.
por: Adegunsoye, Ayodeji, et al.
Publicado: (2019)

Reply to Chase et al. and to Milner et al.
por: Mittel, Aaron M., et al.
Publicado: (2020)

Reply by Xu et al. to Haouzi et al.
por: Xu, Yonghao, et al.
Publicado: (2020)

Reply by Pan et al. to Haouzi et al.
por: Pan, Chun, et al.
Publicado: (2020)

Reply to Topeli et al. and to Akinosoglou et al.
por: Azevedo, Luciano C. P., et al.
Publicado: (2020)

Response to Gould et al. and Vincelli et al.
Publicado: (2017)

Reply to Turnbull et al. and to Hulme et al.
por: Breuer, Oded, et al.
Publicado: (2020)

Reply to Shoemark et al. and to Shapiro et al.
por: Amirav, Israel, et al.
Publicado: (2020)

Reply to Blot et al. and to Inoue et al.
por: McElvaney, Oliver J., et al.
Publicado: (2021)

Reply to Sanfilippo et al. and to Caviedes et al.
por: Arachchillage, Deepa J., et al.
Publicado: (2021)

Reply to Jin et al. and to Sun et al.
por: Boucly, Athénaïs, et al.
Publicado: (2021)

Reply to Nie et al. and Bhammar et al.
por: Peters, Michael C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8hhrgo2o7ogt5l0t9ppfu5oq8b